Last reviewed · How we verify
VIP/ABVD
VIP/ABVD is a chemotherapy regimen used to treat Hodgkin lymphoma.
VIP/ABVD is a chemotherapy regimen used to treat Hodgkin lymphoma. Used for Hodgkin lymphoma.
At a glance
| Generic name | VIP/ABVD |
|---|---|
| Also known as | VIP/ABVD Arm |
| Sponsor | University Hospital, Grenoble |
| Drug class | chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
VIP/ABVD is a combination of four chemotherapy drugs: vinblastine, ifosfamide, prednisone, and doxorubicin. This regimen works by targeting rapidly dividing cancer cells and inducing cell death.
Approved indications
- Hodgkin lymphoma
Common side effects
- Nausea
- Vomiting
- Fatigue
- Hair loss
- Infection
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VIP/ABVD CI brief — competitive landscape report
- VIP/ABVD updates RSS · CI watch RSS
- University Hospital, Grenoble portfolio CI